Risk Factors for Pyogenic Liver Abscess With Carbapenem-resistant Klebsiella Pneumoniae: A Matched Case-control Study

A Matched Case-control Study of Carbapenem Resistant and Carbapenem Sensitive Klebsiella Pneumoniae Infected Pyogenic Liver Abscess

Pyogenic liver abscess (PLA) is a complication of infectious disease, and the most common pathogen of PLA is Klebsiella pneumoniae, while PLA caused by Carbapenem-resistant Klebsiella pneumoniae (CRKP) has become a threat to public health. For achieving a better therapeutic outcome of CRKP related PLA, it is very important to figure out the basic characteristics and risk factors of CRKP-PLA.

A retrospective cohort study was performed in which 15 PLA patients carriage of K pneumoniae were screened at the Xiangya hospital of central south university (changsha, China). The colonization and clinical infection isolates were analyzed by antimicrobial susceptibility testing to identify CRKP. All admission patients diagnosed with PLA who developed CRKP were included, 5 adults PLA patients with CRKP infected and 10 adults PLA patients with Carbapenem sensitive Klebsiella pneumoniae (CSKP) infected were conducted. Univariate and multivariate logistic regression was carried out using a stepwise selection method to compare prognostic factors between CRKP and CSKP groups.

Study Overview

• Status: Completed
• Conditions: Liver Abscess
• Intervention / Treatment: Diagnostic test: drug sensitivity results

• Study Type: Observational
• Enrollment (Actual): 15

Contacts and Locations

Study Locations

• China
  • Changsha, China
    • Jinqing Liu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

18 years of age or older and at least one positive culture reported by the clinical microbiology laboratory for CRKP or CSKP during the hospital length of stay. Klebsiella pneumoniae were isolated and identified in the blood or pus with antibiotic drug sensitivity results.

Description

Inclusion Criteria:

• 18 years of age or older. at least one positive culture reported by the clinical microbiology laboratory for CRKP or CSKP during the hospital length of stay.

Klebsiella pneumoniae were isolated and identified in the blood or pus with antibiotic drug sensitivity results.

Exclusion Criteria:

• Less than 18 years old. patients with missing data without a drug sensitivity results.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Retrospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CRKP-PLA; Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-resistant Klebsiella pneumoniae.	Diagnostic test: drug sensitivity results; drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae
CSKP-PLA; Klebsiella pneumoniae were isolated from pyogenic liver abscess patients' blood or pus and the antibiotic drug sensitivity results shows it is carbapenem-sensitive Klebsiella pneumoniae.	Diagnostic test: drug sensitivity results; drug sensitivity results including the carbapenem-resistant Klebsiella pneumoniae and carbapenem-sensitive Klebsiella pneumoniae

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
the survival rates	2monthes

Collaborators and Investigators

• Sponsor: Xiangya Hospital of Central South University

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2020
• Primary Completion (Actual): June 30, 2020
• Study Completion (Actual): June 30, 2020

Study Registration Dates

• First Submitted: August 29, 2022
• First Submitted That Met QC Criteria: August 29, 2022
• First Posted (Actual): August 30, 2022

Study Record Updates

• Last Update Posted (Actual): August 30, 2022
• Last Update Submitted That Met QC Criteria: August 29, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Lung Diseases; Inflammation; Liver Diseases; Suppuration; Abdominal Abscess; Pneumonia; Abscess; Liver Abscess; Liver Abscess, Pyogenic
• Other Study ID Numbers: 202005055

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No